STACIE KUBICSKO: Open Payments
NPI 1104281633 · HARRISONVILLE, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,582 in 81 payments from 30 companies in 2025. Trend: 2023 $1,659 · 2024 $1,297 · 2025 $1,582
Food & beverage: $1,582
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $188 |
| Otsuka America Pharmaceutical, Inc. | 8 | $150 |
| Novo Nordisk Inc | 7 | $142 |
| SHIELD THERAPEUTICS INC | 2 | $111 |
| Dexcom, Inc. | 5 | $100 |
| Vanda Pharmaceuticals Inc. | 4 | $97 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $78 |
| PFIZER INC. | 4 | $74 |
| Lilly USA, LLC | 4 | $71 |
| AstraZeneca Pharmaceuticals LP | 4 | $60 |
Products named: REXULTI, ACCRUFER, Dexcom G6 Transmitter, Ozempic, FANAPT, CAPLYTA, VRAYLAR, QULIPTA.
Industry payments across MO — which companies pay providers there.
